Oregon Therapeutics
Oregon Therapeutics is focused on developing innovative targeted therapies in oncology, particularly the drug candidate XCE853, which inhibits protein disulfide isomerase. Their mission is to bring this new drug into clinical development within two years, targeting cancers such as ovarian and pancreatic cancer, with potential indications including liver, prostate, head & neck, and orphan cancers.
Industries
Nr. of Employees
small (1-50)
Oregon Therapeutics
3 rue du Colonel Moll 75017, Paris France
Products
Small-molecule protein disulfide isomerase inhibitor (development candidate)
A development-stage small-molecule metabolic inhibitor designed to target protein disulfide isomerase family enzymes for oncology therapy; being advanced toward clinical phase entry.
Small-molecule protein disulfide isomerase inhibitor (development candidate)
A development-stage small-molecule metabolic inhibitor designed to target protein disulfide isomerase family enzymes for oncology therapy; being advanced toward clinical phase entry.
Services
Collaborative research and development engagements with academic groups, CROs and industry partners to support medicinal chemistry, preclinical evaluation and CMC activities.
Collaborative research and development engagements with academic groups, CROs and industry partners to support medicinal chemistry, preclinical evaluation and CMC activities.
Expertise Areas
- Oncology drug discovery
- Medicinal chemistry
- Preclinical translational research
- CMC and chemical process development
Key Technologies
- Small-molecule drug discovery
- Protein disulfide isomerase (PDI) inhibition
- Medicinal chemistry and structure-activity optimization
- Preclinical in vitro and in vivo cancer models
News & Updates
Treatment of Neuroblastoma Cells with Inhibitors of Protein Disulfide Isomerase Upregulates NQO1 Activity
Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity.
Protein disulfide isomerase family mediated redox regulation in cancer.
Roles of Protein Disulfide Isomerase in Breast Cancer.
PDIA6 contributes to aerobic glycolysis and cancer progression in oral squamous cell carcinoma.
Protein disulphide isomerase inhibition as a potential cancer therapeutic strategy.
Treatment of Neuroblastoma Cells with Inhibitors of Protein Disulfide Isomerase Upregulates NQO1 Activity
Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity.
Protein disulfide isomerase family mediated redox regulation in cancer.
Roles of Protein Disulfide Isomerase in Breast Cancer.
PDIA6 contributes to aerobic glycolysis and cancer progression in oral squamous cell carcinoma.
Protein disulphide isomerase inhibition as a potential cancer therapeutic strategy.